EXAS Stock Overview
Provides cancer screening and diagnostic test products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Exact Sciences Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$70.96 |
52 Week High | US$79.62 |
52 Week Low | US$40.62 |
Beta | 1.27 |
11 Month Change | 8.27% |
3 Month Change | 42.86% |
1 Year Change | 6.02% |
33 Year Change | -25.95% |
5 Year Change | -23.53% |
Change since IPO | 381.08% |
Recent News & Updates
Recent updates
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Sep 25Exact Sciences: Cost Optimization And Product Strength
Aug 18Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Aug 14Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23Shareholder Returns
EXAS | US Biotechs | US Market | |
---|---|---|---|
7D | 2.5% | 1.2% | 1.5% |
1Y | 6.0% | 21.1% | 33.1% |
Return vs Industry: EXAS underperformed the US Biotechs industry which returned 21.1% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 33.1% over the past year.
Price Volatility
EXAS volatility | |
---|---|
EXAS Average Weekly Movement | 9.7% |
Biotechs Industry Average Movement | 9.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EXAS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EXAS's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 6,550 | Kevin Conroy | www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
EXAS fundamental statistics | |
---|---|
Market cap | US$13.11b |
Earnings (TTM) | -US$175.01m |
Revenue (TTM) | US$2.61b |
5.0x
P/S Ratio-74.9x
P/E RatioIs EXAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EXAS income statement (TTM) | |
---|---|
Revenue | US$2.61b |
Cost of Revenue | US$700.34m |
Gross Profit | US$1.91b |
Other Expenses | US$2.09b |
Earnings | -US$175.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 05, 2024
Earnings per share (EPS) | -0.95 |
Gross Margin | 73.19% |
Net Profit Margin | -6.70% |
Debt/Equity Ratio | 80.4% |
How did EXAS perform over the long term?
See historical performance and comparison